East Orange VA Medical Center, East Orange, NJ
Is East Orange VA Medical Center registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.
Does East Orange VA Medical Center hold a New Jersey pharmacy license?
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
Has East Orange VA Medical Center had a state board action or FDA letter?
FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Sep 24, 2025) for East Orange VA Medical Center. State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- East Orange VA Medical Center
- Location
- East Orange, NJ
- Type as FDA labels it
- 503A
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 2
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Sep 24, 2025
- FDA Data Dashboard inspections
- No matching site found
- Form 483 text on this page
- 1 Form 483, 3 observations
- State board records
- Not checked
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as East Orange VA Medical Center, a 503A facility, with 3 dated actions.
| Document | |||
|---|---|---|---|
| Sep 24, 2025 | FMD-145 letter | FMD-145 Letter Issued 09/24/2025 | Not linked by FDA |
| Apr 29, 2025 | Form 483 | 483 Issued 04/29/2025 | fda.gov |
| Feb 27, 2020 | Form 483 | 483 Issued 2/27/2020 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.
FDA inspection classifications and published Form 483s
No inspected site under this exact name and city was found in the FDA Data Dashboard on Nov 15, 2026, searching 12,593 US sites with a drug inspection ending Oct 1, 2008 to Oct 23, 2026. FDA may list the site under another legal name, so this is not a finding that it was never inspected.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483 for this site has 3 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Apr 22, 2025 to Apr 29, 2025: 3 observations
- Firm on the cover
- East Orange VA Medical Center, 385 Tremont Ave, East Orange, NJ 07018 -1023
- FEI number
- 3011110195
- Establishment type on the cover
- Producer of Sterile Products
- FDA district office on the cover
- 10 Waterview Blvd., 3rd Floor Parsippany, NJ 07054
- Matched to this page by
- firm name, city and state on the cover; linked from actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Production areas have difficult to clean or contain porous, particle generating, or visibly duty equipment or surfaces.
Specifically,
On 4/22/2025 I observed the following contamination in your firm's Segregated Compounding Area (SCA) located in room <Redacted B4> 202A:
• Rust was observed on the table legs of the work bench approximately 2 feet from the ISO-5 Sterile Compounding <Redacted B4>
• Discoloration was observed on the HEPA pre-filter that is located directly below an an· return vent in the SCA. This pre-filter is a part of the ISO-5 Sterile Compounding <Redacted B4>
On 4/22/2025 I observed the following contamination adjacent to your firm's SCA located in roonm <Redacted B4>167:
• Puddled liquid was observed in the bottom of a cabinet within the closet containing cleaners and a sink used for hand washing prior to production within the SCA. This closet is located dn·ectly adjacent to room <Redacted B4> 167 and doorway to the closet is approximately 10 feet from the SCA entrance.
Observation 2
The sinks are present directly adjacent to the ISO 5 area.
Specifically,
Your firm's Segregated Compounding Area (SCA) located in room <Redacted B4> 202A contains a sink that is approximately three feet from the ISO-5 Compound Aseptic <Redacted B4> and one foot from a storage bin containing materials entered into the ISO-5 <Redacted B4>. Your firm's technicians utilize wipes to diy hands that are located in the same storage bin as components that are introduced to the ISO-5 area, such as sterile gloves. This sink is located within the SCA. Your fnm regularly utilizes this SCA to make drug products for Veterans.
Observation 3
Beta-lactam drugs were produced without providing adequate containment, segregation, and/or cleaning of work surfaces, utensils, and/or personnel to prevent cross-contamination.
Specifically,
Your fir m doe s not have policies in place to deactivate Penicillin and Beta Lactam products after production. Your firm has produced approximately <Redacted B4> HIV bags of Penicillin G Potassium and <Redacted B4> IV bags of Meropenem since January 1st, 2025, in your firm's main Segregated Compounding Area. In addition, your firm has not demonstrated that deactivation of Beta Lactam and Penicillin products occur with the cleaning agents used.
Linked 483s whose text is not shown
- Feb 27, 2020: FDA document 137552: the FEI number and firm name on its cover do not match this page by the rule.
State board of pharmacy records
State board of pharmacy records for New Jersey are not checked: the Division of Consumer Affairs website, which publishes pharmacy permit records and board actions, answers automated requests with a bot challenge, and the state’s public license lookup lists individual licensees but not pharmacy permits; this index does not work around blocks.
This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.